Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of stem cell transplantation procedures.
Lead product is ATIR™ (a donor lymphocyte preparation depleted of alloreactive T-cells) and under development to reduce transplant related mortality following an allogeneic hematopoietic stem cell transplantation.
Kiadis Pharma is located in Amsterdam, The Netherlands.

Web: www.kiadis.com